What Boehringer’s survodutide cardiovascular trial means for obesity approval
Survodutide met its Phase 3 cardiovascular safety goal, but GI discontinuation near 20% could shape Boehringer’s obesity launch strategy.
Pharma & Biotech
Pharma & Biotech
AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver?
AimedBio's BI 4060107 enters Phase 1 testing under a potential $991 million Boehringer Ingelheim deal. Safety and early activity remain unproven.
Pharma & Biotech
What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment
Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.
Medical Devices & Diagnostics
How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy
Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.
Pharma & Biotech
How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Pharma & Biotech
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Pharma & Biotech
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Pharma & Biotech
Boehringer Ingelheim expands Jascayd label to PPF following pivotal trial success
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has
Pharma & Biotech
Why Boehringer’s $10bn U.S. investment and TrumpRx deal may reshape pharma cost dynamics
Boehringer Ingelheim’s $10B U.S. investment and TrumpRx.gov deal may redefine drug pricing and supply chains. Find out what this changes for pharma now.